BCR-ABL is an oncogenic fusion protein with excessive tyrosine-kinase activity, involved in the pathogenesis of chronic myeloid leukemia (CML). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.